Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions

Abstract

Objective. To evaluate the efficacy of bevacizumab and gemcitabine in combination with cisplatin in the treatment of esophageal cancer and the effect on the incidence of adverse reactions. Methods. A total of 100 esophageal cancer patients admitted to our hospital from March 2019 to March 2021 were identified as research subjects and randomized into the control group and the study group, with 50 cases in each group. The control group was treated with gemcitabine combined with cisplatin, and the study group was treated with the triple therapy of bevacizumab, gemcitabine, and cisplatin. The treatment efficiency and the incidence of adverse reactions were compared between the two groups of patients. Results. The total treatment efficiency in the study group was 86%, which was significantly higher than that of 66% in the control group ( P < 0.05 ). After treatment, the levels of vascular endothelial growth factor (VEGF), Cyfra21-1, and C-met were reduced in both groups, with significantly lower levels in the study group than in the control group ( P < 0.05 ). The incidence of all CTCAE, ototoxicity, and nephrotoxicity was comparable between the two groups ( P > 0.05 ). The survival rates of patients in the study group were 88% and 54% at 1 and 2 years after treatment, which were significantly higher than that of 68% and 32% in the control group ( P < 0.05 ). Conclusion. The clinical efficiency of bevacizumab and gemcitabine combined with cisplatin in the treatment of esophageal cancer is remarkable, which improves the survival of patients, and is worthy of clinical promotion and application.

Multifunctional nanoparticle-mediated combining therapy for human diseases

“… – 491 – Gemcitabine and Cisplatin + Bevacizumab vs. Gemcitabine and Cisplatin 2 years n = 50 The total effective rate increased by 20%, the two-year survival rate increased by 22%, and the incidence of adverse reactions decreased. – 492 – Azacitidine + Ivosidenib vs. Azacitidine + Placebo 2 years Ivosidenib ( n = 72) Placebo ( n = 74) Significantly increased event-free survival. ( P = 0.002) Phase 3 493 NCT03173248 Nab-Paclitaxel + Atezolizumab vs. Nab-Paclitaxel + Placebo 2 years n = 451 Significantly prolonged PFS ( P = 0.002) Phase 3 494 NCT02425891 Liposome formulation of irinotecan and floxuridine CPX-1 28 days n = 33 Anti-tumor efficacy against advanced solid tumors Phase 1 495 – CPX-351: Daunorubicin and Cytarabine liposomes vs. 7 + 3: Daunorubicin and Cytarabine Treatment period 30 days; follow-up 5 years.…”

The roles and mechanisms of the lncRNA-miRNA axis in the progression of esophageal cancer: a narrative review

“…VEGFs play an important role in inducing the proliferation of vascular endothelial cells and the formation of new blood vessels. At present, many drugs are used to inhibit angiogenic factors, such as bevacizumab ( 23 ), ramusirumab ( 24 ), apatinib ( 25 ), sorafenib ( 26 ). In addition, according to basic and clinical experiments, there are also everolimus ( 27 ) targeting mammalian target of rapamycin (mTOR) related pathway and rilotumumab ( 28 ) targeting c-Met pathway in esophageal cancer.…”